Latest News of GFR
Greenfire Resources Ltd (GFR) Q3 2024 Earnings Call Highlights: Strong Production Growth and ...
By Yahoo! Finance |
1 week ago
The company plans to repeat its successful drilling program next year with over 15 refill targets remaining. In 2025, they aim to focus on Koar Reservoir targets and finalize refills at Expansion....
Those who invested in Jungfraubahn Holding (VTX:JFN) three years ago are up 21%
By Yahoo! Finance |
2 weeks ago
Jungfraubahn Holding AG (VTX:JFN) saw a 15% drop in share price in the last quarter, but over three years, the company outperformed its market index with a 14% gain....
Are Strong Financial Prospects The Force That Is Driving The Momentum In Siegfried Holding AG's VTX:SFZN) Stock?
By Yahoo! Finance |
1 month ago
Siegfried Holding's stock rose by 16% in the past three months. Analyzing its financial health, the Return on Equity (ROE) stands at 14%, indicating efficient profit generation and future earnings pot...
-
What Is Jungfraubahn Holding AG's (VTX:JFN) Share Price Doing?
By Yahoo! Finance | 1 month agoJungfraubahn Holding AG has seen significant share price movements on the SWX, currently undervalued at CHF176 compared to its intrinsic value of CHF266.66. With stable share prices and modest growth ...
-
RYBREVANT® (amivantamab-vmjw) plus standard of care approved in the U.S. as first and only targeted regimen to cut risk of disease progression by more than half in second-line EGFR-mutated advanced lung cancer
By Yahoo! Finance | 2 months agoThe FDA approved RYBREVANT in combination with chemotherapy for EGFR-mutated NSCLC patients. Results from the Phase 3 MARIPOSA-2 study showed improved outcomes, making it the third new indication for ...
-
Retail investors who hold 46% of Siegfried Holding AG (VTX:SFZN) gained 3.9%, institutions profited as well
By Yahoo! Finance | 2 months agoRetail investors own 46% of Siegfried Holding AG, making them the most powerful group. Despite a recent stock price increase, institutions with 43% ownership also stand to gain. Analyzing shareholder ...
-
RYBREVANT® (amivantamab-vmjw) plus chemotherapy shows positive overall survival trend versus chemotherapy in patients with previously treated EGFR-mutated lung cancer
By Yahoo! Finance | 2 months agoJohnson & Johnson announced positive results from the Phase 3 MARIPOSA-2 study, showing RYBREVANT combined with chemotherapy led to significant and sustained improvement in post-progression outcomes f...
-
Dexamethasone reduces infusion-related reactions in patients with EGFR-mutated non-small cell lung cancer treated with intravenous RYBREVANT® (amivantamab-vmjw)
By Yahoo! Finance | 2 months agoA study by Johnson & Johnson revealed a pre-medication regimen with dexamethasone significantly reduced infusion-related reactions with RYBREVANT for NSCLC patients, showing a three-fold decrease in r...
-
RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) show strong favorable overall survival trend versus osimertinib in EGFR-mutated advanced lung cancer
By Yahoo! Finance | 2 months agoLong-term data from the MARIPOSA study show improved outcomes with RYBREVANT plus LAZCLUZE™ compared to osimertinib in first-line treatment for NSCLC....
-
Estimating The Fair Value Of Siegfried Holding AG (VTX:SFZN)
By Yahoo! Finance | 4 months agoAn analyst price target for Siegfried Holding AG (VTX:SFZN) is 20% above the fair value estimate. By using a Discounted Cash Flow (DCF) model, the company appears to be fairly priced based on future c...
-
Health Canada Authorizes RYBREVANT® (amivantamab) in Combination with Carboplatin and Pemetrexed as the Only Targeted First-line Treatment Approved for Patients with Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
By Yahoo! Finance | 4 months agoThe Phase 3 PAPILLON study demonstrated that RYBREVANT with carboplatin and pemetrexed significantly enhances progression-free survival in NSCLC patients with EGFR exon 20 insertion mutations....
-
Subcutaneous amivantamab Biologics License Application submitted to U.S. FDA for patients with EGFR-mutated non-small cell lung cancer
By Yahoo! Finance | 5 months agoJohnson & Johnson submitted a Biologics License Application for subcutaneous amivantamab for non-small cell lung cancer. Results from PALOMA-3 study revealed benefits like reduced infusion reactions a...
-
Although Greenfire Resources Ltd. (NYSE:GFR) insiders have sold lately, they have the highest ownership with 46% stake
By Yahoo! Finance | 5 months agoGreenfire Resources Ltd. (NYSE:GFR) has 4 main investors with a majority stake of 57%. Insiders hold 46% ownership, institutions less than 5%, and hedge funds 24%....